• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
DAIICHI SANKYO - Edoxaban Gets Edge as Key Japanese Factor-Xa Inhibitors Fall! Product Image

DAIICHI SANKYO - Edoxaban Gets Edge as Key Japanese Factor-Xa Inhibitors Fall!

  • Published: September 2011
  • Region: Japan
  • MP Advisors

Recent failures of Edoxaban’s key competitor factor-Xa inhibitors from Japan - YM 150 (Astellas) and TAK-442 (Takeda), the closest candidate in Japan now is Xarelto (Bayer), which is still ~1 years away from hitting the market. Edoxaban is the first and only approved factor-Xa inhibitor in Japan for prevention of VTE, though Japanese VTE opportunity is not big but it will enhance investors’ confidence regarding its global success where the opportunity is huge. Edoxaban is behind Xarelto in development for AF (~2 years). However, considering its high market potential it remains attractive as it is the only drug that has shown dose response in this class

- Edoxaban
- YM150
- TAK-442
- Factor Xa candidates
- Xarelto
- Apixaban
- ICT data
- VTE
- AF
- Factor Xa pipeline
- Anticoagulants market
- Betrixaban
- Astellas
- Takeda
- Bayer

Note: Product cover images may vary from those shown

RELATED PRODUCTS